Showing results (201-210 of 447) with videos related to

Sort By:
Pageof 45
Japanese Journal of Clinical Oncology|August 21, 2018
Study protocol for J-SUPPORT 1604 (J-FORCE): a randomized, double blind, placebo-controlled Phase III study evaluating olanzapine (5 mg) plus standard triple antiemetic therapy for prevention of chemotherapy induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapyHironobu Hashimoto, Masakazu Abe, Takako Yanai, et al.
JTO Clinical and Research Reports|September 30, 2021
Clinical Efficacy and Safety of Nivolumab in Japanese Patients With Malignant Pleural Mesothelioma: 3-Year Results of the MERIT StudyNobukazu Fujimoto, Morihito Okada, Takashi Kijima, et al.
International Journal of Clinical Oncology|October 12, 2012
Moderate renal dysfunction may not require a cisplatin dose reduction: a retrospective study of cancer patients with renal impairmentTomoko Ogawa, Seiji Niho, Shunji Nagai, et al.
NPJ Precision Oncology|January 15, 2025
Diversity of TCR repertoire predicts recurrence after CRT followed by durvalumab in patients with NSCLCMasayuki Shirasawa, Tatsuya Yoshida, Takaji Matsutani, et al.
JAMA Oncology|November 22, 2023
First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations: The UNICORN Phase 2 Nonrandomized Clinical TrialYusuke Okuma, Kaoru Kubota, Mototsugu Shimokawa, et al.
Clinical Lung Cancer|November 2, 2025
Genomic Profiles as Predictors of Occult Lymph Node Metastasis and Clinical Outcomes in Early-Stage Clinical N0 Non-Small Cell Lung CancerChihiro Takemura, Tatsuya Yoshida, Yukihiro Yoshida, et al.
Lung Cancer (Amsterdam, Netherlands)|May 19, 2020
Salvage surgery after chemotherapy and/or radiotherapy including SBRT and proton therapy: A consecutive analysis of 38 patientsAki K Kobayashi, Hidehito Horinouchi, Yuko Nakayama, et al.
Cancer Science|September 6, 2007
Epidermal growth factor receptor mutation status and clinicopathological features of combined small cell carcinoma with adenocarcinoma of the lungTomoya Fukui, Koji Tsuta, Koh Furuta, et al.
Cancer Science|October 22, 2009
Phase I study of TLR9 agonist PF-3512676 in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancerKazuhiko Yamada, Masao Nakao, Chikara Fukuyama, et al.
Carcinogenesis|October 3, 2017
The genomic and epigenomic landscape in thymic carcinomaMotonobu Saito, Yutaka Fujiwara, Tetsuhiko Asao, et al.
Pageof 45